LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.

YTS104 - BriSTAR Immunotech, Beijing Qingyi Taike Pharma

http://www.ncbi.nlm.nih.gov/pubmed/38813706

Fangshuo Feng; Gang An; Hao Sun; Jingyu Xu; Lanting Liu; Lei Lei; Lixin Gong; Lugui Qiu; Mu Hao; Teng Fang; Tingyu Wang; Wei Rui; Weiwei Sui; Xin Lin; Xiyue Sun; Xueqiang Zhao; Yuxuan Liu; Zhen Yu

May 30, 2024